Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 275

Corporates buy into Biofourmis in $35m round

MassMutual Ventures co-led the healthcare data platform developer's series B round, which also featured Aviva Ventures and Jianke.

May 23, 2019

GCV Symposium 2019: GHIF's rolling thunder

William Taranto spoke about his near decade at Merck Global Health Innovation Fund and how corporate venturing has evolved in that time.

May 22, 2019

Corporates coax third MD Start to close

Medtronic, LivaNova and Baxter Healthcare have helped commit $53.5m for the third medical device-based fund to be raised under the MD Start moniker.

May 22, 2019

Cala Health holds on to $50m

Alphabet, Novartis and Johnson & Johnson have contributed to a series C round for Cala Health, which is preparing to release its wearable hand-tremor treatment device.

May 22, 2019

SIG helps Shanzhen take care of funding

Susquehanna International Group has led a series B round for elderly healthcare services provider Shanzhen that was in the eight-figure dollar range.

May 22, 2019

Schrödinger boxes up $110m

The drug development software provider has added $25m to an Alphabet and Wuxi AppTech-backed first tranche it closed in January.

May 21, 2019

Reneo generates $50m in series A round

Lundbeckfond Ventures contributed to a round that will fund clinical trials for Reneo Pharmaceuticals' mitochondrial disease therapies.

May 21, 2019

Paradigm Diagnostics packs in $15m

OSF Healthcare Ventures was among the participants in an extension to the cancer testing technology provider's series B round, which has now reached $15m.

May 20, 2019

SinoUnited Health seizes series B funding

SinoUnited secured $14.4m and the Kuok Group-backed round will support the hiring of more doctors and the opening of additional healthcare centres.

May 20, 2019

Storm attracts more series A funding

M Ventures, Pfizer Ventures and Taiho Ventures all returned to help boost cancer drug developer Storm Therapeutics' series A round to $38.2m.

May 20, 2019

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here